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TITLE OF CASE Do not include “a case report” 
 
Hereditary selective cobalamin malabsorption and concurrent pancreatitis in a young Border 
Collie 
SUMMARY Up to 150 words summarising the case presentation and outcome (this 
will be freely available online) 
 
 
A one year old male neutered Border Collie presented with failure to gain weight, lethargy, 
intermittent leukopenia, borderline anaemia and intermittent gastrointestinal symptoms. He was 
diagnosed with pancreatitis based on a blood results and abdominal ultrasonography and 
hereditary selective cobalamin malabsorption based on hypocobalaminaemia, methylmalonic 
aciduria and genetic testing for cubilin mutation. The dog responded to oral cobalamin 
supplementation with resolution of clinical signs and normalisation of serum cobalamin. There 
was no recurrence of signs after 27 months of follow-up. An association between organic 
acidaemias and pancreatitis has been reported in humans but to the authors’ knowledge, this is the 
first report of hereditary selective cobalamin malabsorption and concurrent pancreatitis in a dog. 
Furthermore, this is the first report of inherited canine cobalamin deficiency responding to oral 
cobalamin supplementation.  
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BACKGROUND Why you think this case is important – why did you write it up? 
Hereditary selective cobalamin malabsorption has previously been described in Border 
Collies1,2,3,4,5,6, Giant Schnauzers7,8, Shar Peis9,10, Beagles11,12,13,14,15,16 and Australian 
Shepherds17. Classical clinical signs include lethargy, neurological signs and failure to thrive.  
The condition closely resembles selective intestinal cobalamin malabsorption (Imerslund-
Grasbeck syndrome) in humans18,19. 
 
Pancreatitis is the most common condition of the exocrine pancreas in dogs. The majority of 
cases are classed as idiopathic, although other postulated causes include hypertriglyceridaemia, 
endocrinopathies, adverse drug reactions, prior surgery, infections and high fat diets20. An 
association between MMA acidaemia and the development of pancreatitis has been documented 
in the human literature but not yet reported in dogs21,22.  The mechanism is unknown, although it 
has been suggested that inhibition of mitochondrial function and free radical formation may play 
a role21.  
 
 
 
 
CASE PRESENTATION Presenting features, clinical and environmental history 
A one year old male neutered Border Collie was referred for investigation of an 8-month history 
of failure to gain weight, lethargy and intermittent gastrointestinal symptoms (anorexia, vomiting 
and diarrhoea). Investigations performed by the referring veterinary surgeon included faecal 
analysis, haematology, biochemistry, trypsin-like immunoreactivity (TLI), folate and cobalamin 
measurements and abdominal ultrasound (Tables 1 and 2).  
Measurement (reference range) 23/12/2014 07/05/2015 17/08/2015 
Haematocrit (37-55%) 32.9 37 45.5 
Reticulocytes (10-110 K/µL) 28 40.6 39.1 
White cell count (5.5-16.9 x109/L) 4.24 4.32 3.04 
Neutrophils (3-12 x 109/L) 1.79 2.10 1.10 
Lymphocytes (0.5-4.9 x 109/L) 1.79 1.60 1.36 
Monocytes (0.3-2 x 109/L) 0.38 0.48 0.51 
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Table 1: Haematology results obtained prior to referral (abnormal results in bold) 
 
Measurement 
(reference range) 
23/12/2014 07/05/2015 17/08/2015 
Glucose (4.28-8.34 
mmol/L) 
5.78 4.06 5.39 
Urea (2.5-10.4 
mmol/L) 
4.3 6.4 8.6 
Creatinine (27-106 
µmol/L) 
71 71 62 
Phosphate (1.65-3.36 
mmol/L) 
2.07 1.81 1.52 
Total calcium (1.95-
3.15 mmol/L) 
2.43 2.38 2.38 
Total protein (48-72 
g/L) 
57 50 55 
Albumin (21-36 g/L) 26 27 28 
Globulin (23-38 g/L) 30 23 27 
ALT (8-75 U/L) 56 38 66 
ALP (46-337 U/L) 131 207 313 
Total bilirubin (0-14 
µmol/L) 
<2 9 3 
Cholesterol (2.58-
10.32 mmol/L) 
2.99 2.99 2.55 
TLI (6.1-35 µg/L)  21.3  
Folate (8.2-13.5 
µg/L) 
 11.9  
Cobalamin (>= 275 
ng/L) 
 <150  
Spec CPL (<=200 
µg/L) 
 89  
Table 2: Biochemistry, TLI, folate, cobalamin and spec CPL results obtained prior to referral 
(abnormal results in bold) 
 
 
Persistent leukopenia, neutropenia and borderline anaemia, as well as hypocobalaminaemia were 
documented prior to referral. Faecal analysis and abdominal ultrasound (performed by a board-
certified radiologist) were unremarkable. Clinical improvement with a combination of low fat diet 
(Royal Canin Gastrointestinal Low Fat) and metronidazole treatment was noted. The dog did not 
receive cobalamin or multivitamin supplementation prior to referral. The patient was referred 
because his symptoms recurred. Physical examination at the referral centre revealed the dog to be 
thin (body condition score 2/9) and depressed. His mucous membranes were pink but tacky. 
Eosinophils (0.1-1.49 x 109/L) 0.25 0.13 0.06 
Basophils (0-0.1 x 109/L) 0.04 0.01 0.01 
Platelets (175-500 K/µL) 115 516 422 
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Thoracic auscultation was unremarkable and he displayed cranial abdominal discomfort on 
palpation. He was normothermic.  
INVESTIGATIONS If relevant 
Haematology, biochemistry, urinalysis, basal cortisol, TLI, folate, cobalamin and bile acid 
stimulation test were obtained (Tables 3 and 4).  
Measurement  Value Reference range 
White blood cell count  8.68 6-17 x 109/L 
Neutrophils 4.30 3-11.5 x 109/L 
Lymphocytes 3.3 1-4.3 x 109/L 
Monocytes 0.69 0.2-1.5 x 109/L 
Eosinophils 0.35 0.1-1.3 x 109/L 
Basophils 0.01 0-0.5 x 109/L 
Red blood cell count 5.94 5.5-8.5 x 1012/L 
Haematocrit 38.7 37-55% 
Platelets 158 175-500 x 109/L 
Table 3: Haematology results on presentation (abnormal results in bold) 
 
Measurement Value Reference range 
Sodium 145  135-155 mmol/L 
Potassium 4 3.6-5.7 mmol/L 
Chloride 111 103-120 mmol/L 
Urea 5.1 2.5-7.4 mmol/L 
Creatinine 81 34-136 umol/L 
Glucose 5.6 3.4-5.6 mmol/L 
Total protein  54 55-77 g/L 
Albumin 28 25-41 g/L 
Globulin 26 24-47 g/L 
Calcium 2.36 2.2-2.9 mmol/L 
Phosphate  1.67 0.8-1.73 mmol/L 
ALT 57 14-67 IU/L 
AST  504 12-49 IU/L 
CK 213 42-206 IU/L 
GGT 6 0-10 IU/L 
ALP 211 26-107 IU/L 
Total bilirubin 5.3 0-12 umol/L 
Cholesterol 3 3.3-6.5 mmol/L 
Triglyceride 0.5 0.4-1.3 mmol/L 
Amylase 1619 256-1609 IU/L 
Lipase (DGGR) 525 0-200 IU/L 
C-reactive protein 2.6 0-8.2 mg/L 
TLI >50 6.1-35 µg/L 
Folate 7.9 3-13 ng/ml 
Cobalamin 286 200- ng/L 
Post-prandial bile acids 8 0-22.5 umol/L 
Basal cortisol 163 29-250 nmol/L 
Table 4: Biochemistry, TLI, folate, cobalamin, post-prandial bile acids and basal cortisol on 
presentation (abnormal results in bold) 
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Haematology was unremarkable. A serum biochemical profile documented mild 
hypoproteinaemia (54 g/L; 55-57) and hypocholesterolaemia (3 mmol/L; 3.3-6.5) considered 
secondary to gastrointestinal loss. He had elevated concentrations of aspartate aminotransferase 
(AST) (504 IU/L; normal 12-49), creatine kinase (CK) (211 IU/L; normal 42-206), alkaline 
phosphatase (ALP) (211 IU/L; normal 26-107) and 1,2-o-dilauryl-rac-glycero-3-glutaric acid 
(DGGR) lipase (525 IU/L; 0-200). Urinalysis documented mild proteinuria (urine 
protein:creatinine ratio 0.72; normal 0-0.4), bilirubinuria (+++), haematuria (++) and urine 
specific gravity was 1.032. Urine sediment examination and culture were negative. Cobalamin 
was at the bottom end of the normal range (286 ng/L (200-)). TLI was >50 µg/L consistent with 
pancreatic inflammation. Basal cortisol, folate and bile acid stimulation test results were within 
normal limits. Abdominal ultrasound was performed and documented a markedly enlarged right 
pancreatic limb with surrounding hyperechoic mesentery consistent with pancreatitis (Figure 1). 
During hospitalisation, the patient became persistently bradycardic so an ECG examination was 
obtained before and after 0.02mg/kg intramuscular atropine administration (Figures 2 and 3). This 
showed abolition of sinus bradycardia with administration of atropine.  
DIFFERENTIAL DIAGNOSIS If relevant 
Differentials for hypocobalaminaemia include dietary insufficiency of vitamin B12, small 
intestinal bacterial overgrowth (due to utilisation of cobalamin by intestinal microorganisms), 
intestinal disease leading to malasorption, inborn error of cellular cobalamin metabolism, 
pancreatitis, exocrine pancreatic insufficiency or hereditary selective cobalamin malabsorption. 
Inborn errors of cellular cobalamin metabolism are an important cause of cobalamin deficiency in 
children, but not in dogs. Dietary deficiency has not been shown to lead to clinical signs of 
cobalamin deficiency in dogs and cats23,24, however, vegetarian and vegan diets have been shown 
to be cobalamin deficient25.  Differentials for methylmalonic aciduria inborn errors of cobalamin 
malabsorption, postprandial and hereditary selective cobalamin malabsorption. 
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TREATMENT If relevant  
The patient was initially treated with intravenous Lactated Ringers at 4ml/kg/hour, 1 mg/kg 
subcutaneous maropitant (Cerenia, Zoetis, UK) SID, 0.02 mg/kg intravenous buprenorphine 
(Vetergesic, Alstoe, UK) IV QID, 2 mg/kg intravenous ranitidine (Zantac, Glaxo Wellcome, UK) 
BID and 10 mg/kg PO paracetamol (Pardale, Dechra, UK) BID.  
OUTCOME AND FOLLOW-UP   
The patient was discharged after 6 days following supportive treatment for pancreatitis. 
Cobalamin was subsequently re-measured four weeks after initial presentation and was subnormal 
(<150 pg/ml), despite clinical improvement (Table 5).  
Table 5: Sequential cobalamin measurements for this patient. Cobalamin supplementation was 
commenced following the documentation of hypocobalaminaemia in September 2015 
 
A urine sample was submitted to the Metabolic Genetic Screening Laboratory, University of 
Pennsylvania for a MMA spot test which was positive consistent with methylmalonic aciduria. 
Hypocobalaminaemia was treated with 500µg cyanocobalamin PO SID. A DNA test was 
obtained to assess for mutation of the CUBN gene (Animal Health Trust, United Kingdom) and 
the patient was homozygous for the genetic mutation consistent with a diagnosis of Imerslund-
Grasbeck syndrome. Cobalamin levels were re-measured 730 days after starting cobalamin 
supplementation and were 974 ng/L (ref >275). A repeat MMA urine test was not performed. 
Telephone consultation with the owner 27 months after initial presentation reported that the dog 
was very well in himself with no recurrence of clinical signs and he now weighed 20kg (Figures 4 
and 5).  
Measurement 
(reference 
range) 
07/05/20
15 
19/08/2015 22/09/2015 19/10/201
5 
24/11/2015 18/03/2016 27/09/2017 
Cobalamin 
(>=275 ng/L) 
<150 286 <150 373 489 >1000 974 
DISCUSSION Include a very brief review of similar published cases  
This is the first report of pancreatitis associated with hereditary selective cobalamin 
malabsorption in a dog. Diagnosis of Imerslund-Grasbeck syndrome was made on the basis of a 
combination of low serum cobalamin concentrations, methylmalonic aciduria, DNA testing, age 
and breed of the dog and excellent clinical response to cobalamin supplementation. An interesting 
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aspect of this case was the initial serum cobalamin levels at presentation in spite of low 
concentrations measured by the referring vet. Serum cobalamin levels do not always correlate 
with body stores26. Dogs with serum cobalamin in the low normal range of the reference interval 
and concurrently increased serum MMA have been previously reported, suggesting a cobalamin 
deficiency at the cellular level3,27. However, dogs with early hypocobalaminaemia 
(eucobalaminaemia and elevated MMA) tend to be subclinical. Interestingly, MMA 
concentrations in healthy Border Collies have been shown to be significantly higher than healthy 
control dogs consistent with benign methylmalonic aciduria3. It is unlikely that the high MMA in 
the presence of eucobalaminaemia reflected benign methylmalonic aciduria, given the genetic 
testing results.  MMA values in sick Border Collies with Imerslund-Gräsbeck syndrome in the 
literature that had not received cobalamin supplementation were always high (range 1800-6665 
mmol/mol creatinine; reference range <4.2, or 1731-9142 mg/g creatinine; reference range 
<10)1,2,3,4,5. Quantification of MMA aciduria was not confirmed in this case which would have 
been useful given that Border Collies with hereditary cobalamin malabsorption tended to have 
much higher MMA values3 and would have decreased the risk of a false positive result. However, 
the spot test has been shown to be useful in humans with no false positives documented in healthy 
patients and patients with other organic acidaemias28. 
 
 
Hereditary cobalamin deficiency was confirmed in this case who was homozygous for mutation 
in the CUBN gene. This is an autosomal recessive trait in Border Collies and the mutation in the 
CUBN gene encoding cubilin (CUBN:c.8392delC variant). This is a single base pair deletion 
predicted to cause frame shift and premature stop codon in CUBN gene.  The carrier frequency of 
this mutation in Border Collies is 6.2%29. Dietary cobalamin is released and binds to R-protein 
and enters the duodenum. In the duodenum, the R protein-cobalamin complex is broken down by 
pancreatic proteases and cobalamin binds to intrinsic factor (IF) (produced in the stomach and 
pancreas of dogs). Cobalamin-IF complex is then absorbed by specific receptors (the cubam 
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receptor consisting of 2 separate subuits:  amnionless (AMN) and cubilin (CUBN)) on the 
enterocytes in the ileum5. Ileal absorption is impaired in Border Collies due to the mutation in the 
CUBN gene. Cobalamin is required for the conversion of homocysteine to methionine and for the 
conversion of methylmalonyl coenzyme A to succinyl CoA; this results in accumulation of 
plasma homocysteine and methylmalonic acid and the development of elevated plasma 
homocysteine levels and methylmalonic aciduria1,5,30. Urea cycle dysfunction and 
hyperammonaemia have also been described in dogs leading to neurological signs1,31  but were 
not reported in this case.  
 
The patient had clinical signs consistent with cobalamin deficiency: - failure to gain weight, 
lethargy and intermittent gastrointestinal signs and anorexia4,12. Weight loss occurs because 
decreased methionine synthase levels can lead to a deficiency in active folate which can impair 
DNA replication, particularly in rapidly dividing cells. This can lead to malabsorption of nutrients 
and reduced food intake4,31. Interestingly, the patient had a bradyarrhythmia which was reversible 
with atropine; bradyarrhythmias have previously been documented in dogs with selective 
cobalamin malabsorption4,11. They are also recognised in humans and are thought to occur due to 
dysfunction of the autonomic nervous system32.  
 
Haematological abnormalities are commonly reported in cobalamin deficiency and were 
intermittently present in this dog although, cobalamin deficiency in Border Collies is not always 
associated with haematological abnormalities4. Haematological abnormalities commonly reported 
in cobalamin deficient dogs include normocytic normochromic anaemia and neutropenia4,12. This 
patient had historical evidence of neutropenia and borderline low PCV. Biochemical 
abnormalities noted in this case included mild hypoproteinaemia and hypocholesterolaemia which 
could reflect intestinal malabsorption. Elevated AST (as seen in this case) has been shown to 
correlate with elevated homocysteine levels in patients with cobalamin deficiency and is thought 
to reflect increased metabolic activity4. Mildly elevated ALP was likely reactive (however, 
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increased bone turnover due to young age could also be contributing) and elevated DGGR lipase 
was considered due to pancreatitis. Hyperlipasaemia has been associated with prior corticosteroid 
use, however, this patient had not received steroids prior to referral. Mild proteinuria (as noted in 
this case) is well documented in dogs with selective cobalamin malabsorption2,3,5,7,12. This is 
thought to occur due to the absence of Cubam complex receptors in renal tubular cells which 
results in reduced albumin reabsorption33.  
 
6-73% of dogs with chronic enteropathies have concurrent hypocobalaminaemia34,35,36,37,38. 
Elevated MMA concentrations are also seen in approximately 25% of these cases38. The 
mechanism for cobalamin deficiency is due to damage to the ideal mucosal receptors for binding 
of cobalamin-intrinsic factor complexes39. It is impossible to exclude significant gastrointestinal 
inflammation and malabsorption as a concurrent cause of hypocobalaminaemia in this case, 
however, the compatible genetic testing, the resolution of clinical signs and weight gain in the 
long-term after receiving only treatment with cobalamin, make this less likely. Furthermore, there 
was only a short duration of gastrointestinal signs and an absence of hypoalbuminaemia. All dogs 
with hypocobalaminaemia due to gastrointestinal disease in one study had concurrent 
hypoalbuminaemia27.  
 
Pancreatitis was diagnosed in this case by a combination of clinical signs, elevated DGGR lipase 
and TLI and abdominal ultrasound findings consistent with pancreatitis (enlarged and hypoechoic 
pancreas with surrounding hyperechoic mesentery). Pancreatitis can affect dogs of any age, but 
the majority of dogs are middle-aged to old so to diagnose pancreatitis in this dog at one year old 
was unusual and adds weight to the association with cobalamin deficiency20. Although the 
clinical signs of cobalamin deficiency and pancreatitis are similar, abdominal pain is not a 
recognised clinical sign of cobalamin deficiency. The patient responded to symptomatic treatment 
for pancreatitis and was only diagnosed with and treated for hereditary cobalamin malabsorption 
4 weeks after initial presentation which is suggestive that the dogs presenting clinical signs were 
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due to pancreatitis. There is an association between MMA organic acidaemias and pancreatitis in 
children21,22. These cases had inherited disorders of organic acid metabolism. None of these cases 
had Imerslund-Gräsbeck syndrome. Some of the cases in the human literature had chronic 
pancreatitis and therefore it is also possible that this case had chronic pancreatitis, however, this 
would not be possible to confirm without histology40. Proposed mechanisms discussed in the 
human literature include inappropriate pancreatic enzyme activation and the inability of the 
pancreas to withstand metabolic stresses that are normally encountered. Inhibition of 
mitochondrial function and free radical formation may play a role21. We postulate that this case 
represents pancreatitis which was an effect of cellular cobalamin deficiency rather than the cause 
of cobalamin deficiency, given that this case had documented hereditary cobalamin deficiency 
and the pancreatitis did not recur after effective supplementation. However, there have been 
reports of human pernicious anaemia (leading to cobalamin deficiency) leading to the 
development of small intestinal changes and therefore the potential that cobalamin deficiency 
itself can lead to primary manifestations of gastrointestinal disease41. Furthermore, there is a 
postulated association between hyperhomocysteinaemia and the development of pancreatitis in 
humans due to its role in vascular dysfunction, microthrombosis and inflammatory conditions 
therefore it is also possible that elevated homocysteine levels (due to cobalamin deficiency) could 
have triggered pancreatitis in this case42.Therefore, it is also reasonable to suggest that 
pancreatitis could have resulted directly from a cobalamin deficiency. The association between 
MMA acidaemia and pancreatitis is interesting in this case, however, the lack of follow-up MMA 
to confirm resolution of MMA acidaemia with treatment for pancreatitis, is a significant 
limitation. However, the patient did not have any further episodes of pancreatitis in a two-year 
follow up period following successful treatment of cobalamin deficiency.  
Oral cobalamin treatment has been shown to be effective in dogs with hypocobalaminaemia due 
to chronic enteropathies39. Oral cobalamin in human cobalamin deficiency has also been shown to 
be effective43,44,45,46. It is thought that in humans approximately 1% of free cobalamin is absorbed 
across the small intestine by passive diffusion, independently of intrinsic factor44 which might 
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explain the response to treatment in this dog. Adequate response to treatment is documented by a 
combination of increased cobalamin and decreased MMA8. We were able to document persistent 
cobalamin levels within the normal range in this dog with over 2 years of follow-up. 
 
The limitations of this study include the fact that methylmalonic aciduria was not quantified by 
organic acid gas chromatography and was not re-measured to document resolution following 
cobalamin supplementation. Homocysteine concentrations were not measured; 
hyperhomocysteinaemia has been reported in dogs with cobalamin deficiency5,27 and would be 
interesting to explore further, given the potential causal association with pancreatitis. 
 
The outcome in this case was excellent with complete resolution of clinical signs following 
cobalamin supplementation. Furthermore, over a two-year follow-up period, the patient did not 
have any recurrence of pancreatitis. This suggests an excellent prognosis for dogs with 
pancreatitis due to cobalamin deficiency, provided that the cause is identified and treated and 
stresses the importance of considering this as a differential diagnosis for pancreatitis in a young 
dog of a susceptible breed.  
LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points – this is a required 
field 
 Cobalamin deficiency should be considered as a cause of failure to thrive and concurrent 
pancreatitis in young Border Collies 
 Hereditary selective cobalamin malabsorption can be diagnosed by genetic testing 
 Pancreatitis may be caused by methylmalonic aciduria in dogs 
 Hereditary selective cobalamin malabsorption can be successfully treated with oral 
cobalamin supplementation. 
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FIGURE/VIDEO CAPTIONS figures should NOT be embedded in this document 
 
Figure 1: Abdominal ultrasound image documenting an enlarged right pancreatic limb with 
surrounding hyperechoic mesentery. 
 
Figure 2: ECG recording documenting sinus bradycardia. 
 
Figure 3: ECG recording following intramuscular administration of atropine documenting 
abolition of sinus bradycardia.  
 
Figure 4: Patient before diagnosis of hereditary selective cobalamin malabsorption 
 
Figure 5: Patient following resolution of pancreatitis and institution of cobalamin 
supplementation.  
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